Our Partners
The annual support received from our partners plays a critical role in helping us improve and sustain care for people with bleeding disorders around the world. We are grateful to our partners for investing in our community and their steadfast belief in the work we do every day in pursuit of our shared vision of Treatment for All.
The Global Partnership Recognition Program is based on our partners’ overall annual support and recognizes multi-year commitments and alignment with our strategic priorities. We are pleased to acknowledge our 2020 Visionary, Leadership and Collaborating Partners.
VISIONARY PARTNERS
LEADERSHIP PARTNERS
COLLABORATING PARTNERS
WFH Corporate Partner Program
For more information about the WFH Corporate Partner Program, please contact our Corporate Relations Manager at [email protected].
Corporate Relations Policy
Corporate support is indispensable for the WFH to fulfill its mission-related activities, goals and objectives. Therefore, the WFH will accept corporate support so long as it is in accordance with the principles of our Corporate Relation Policy.
Corporate Partners News
Visit our Corporate Partners News webpage for news on our corporate partners and to read press releases of interest to the global bleeding disorders community.
Patron
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. Having partnered with the hemophilia community over the past 30 years, we have a deep understanding of the evolving needs and aspirations of people with hemophilia. Through the WFH Humanitarian Aid Program, Bayer seeks to support researchers, healthcare professionals and patient groups to help people with hemophilia A who would have otherwise limited to no access to treatment.
For more information, go to www.bayer.com.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries.
For more information visit at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
Sanofi Genzyme is honored to partner with WFH. We are unwavering in our commitment to advance standards of care through ground-breaking science – with a goal to improve the health and lives of people living with bleeding disorders, breaking barriers to redefine what they can expect from treatment today and tomorrow. We are partnering with WFH on important initiatives, striving to increase awareness, make a lasting impact and empower people living with bleeding disorders so they can lead bold, healthy lives on their own terms.
For more information visit https://www.sanofigenzyme.com/en/areas-of-focus/rare-blood-disorders.
At Sobi, we are dedicated to providing access to innovative treatments that transform life for people with rare diseases. As a biopharmaceutical company specialising in rare diseases, we bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. We believe in the potential of the people we are dedicated to serving.
For more information visit https://www.sobi.com/en/haematology.
Takeda’s 30-year partnership with the WFH is driven by our belief that every bleed matters and that all men and women with a rare bleeding disorder, wherever they live, should have access to comprehensive, personalized care.
The WFH and its NMOs have made significant progress in improving diagnosis and access to care, and Takeda has supported many of the WFH’s programs including the Global Alliance for Progress and the World Bleeding Disorder Registry.
Takeda is proud to support the WFH in advancing evidence-based advocacy and achieving better standards of care for everyone with a rare bleeding disorder globally.
For more information visit https://www.takeda.com.
The National Hemophilia Foundation helps advance our mission on several fronts. They inspire others to follow their lead as a founding champion of the NHF Chapter Challenge. Their commitment to equality of access is demonstrated in their support of the Cornerstone Initiative, which lays the foundation for care in the world's most underserved regions, as well as programs that aim to raise awareness and improve care of women with bleeding disorders and those with von Willebrand disease. We also benefit from their steadfast engagement with various programs including the WFH Twinning Program and their individual leaders’ contribution to our leadership and committees.
Hemophilia of Georgia has stood with us for over three decades, playing an early role in distributing donated factor via the WFH Humanitarian Aid program. Our relationship has deepened over the years as they continued to support this program and came on board as a founding Chapter Challenge champion in 2016. Their belief in educating future leaders is clear in their investment in the Youth Leadership Workshops, which has led to the training of over 50 young adults. They also support workshops devoted to educating providers and patient leaders on how to collect and use data to advocate for better patient care. Their staff generously volunteer their time as trainers and as well as
serving on various committees.
Recognizing that training women leaders ensures the diversity our community need to thrive; the Hemophilia Alliance has been a longtime supporter of the Susan Skinner Memorial Fund. They deepened their engagement with the global community through the establishment of the Travel Grant Program, which allows US-based multidisciplinary healthcare professionals the opportunity to attend WFH global training workshops. The wealth of experience and perspective attendees bring back home to their communities helps patients across the country. Their patience and support as we grappled with changing norms in these challenging times gave us the flexibility to meet our community’s needs with revamped programming.